

Lymphopenia and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Hospitalized Obstetric Patients

Cassandra R. Duffy, MD, MPH, Jessica M. Hart, MD, Anna M. Modest, PhD, Michele R. Hacker, ScD, Toni Golen, MD, Yunping Li, MD, MSc, Chloe Zera, MD, MPH, Scott A. Shainker, DO, MS, Preeti Mehrotra, MD, MPH, Rebecca Zash, MD, and Blair J. Wylie, MD, MPH

INTRODUCTION

Significant concern exists regarding asymptomatic infections in the ongoing coronavirus disease 2019 (COVID-19) pandemic.¹⁻³ Reports from New York City demonstrate considerable prevalence of asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among pregnant patients and several cases of extensive health care

worker exposure during deliveries.⁴⁻⁶ Lymphopenia has been described as a common and early laboratory test abnormality associated with COVID-19 infection.⁷ Given an inability to perform universal testing at our institution secondary to supply chain limitations, we explored a strategy of obtaining white blood cell (WBC) count differentials for all patients admitted to our obstetric unit. We sought to examine whether lymphopenia identified asymptomatic SARS-CoV-2 infection and to assess whether lymphopenia could discriminate the presence of infection in symptomatic patients under investigation for COVID-19.

METHODS

We implemented a policy of universal automated WBC count differential testing for all obstetric patients from April 1 through April 14, 2020. Patients with lymphopenia (defined as absolute lymphocyte count less than $0.8 \times 10^3/\text{microliter}$ ^{8,9}) underwent COVID-19 testing using a nasopharyngeal swab test (PANDAA qDx real-time polymerase chain reaction), as did all symptomatic patients. To assess whether lymphopenia could predict COVID-19 infection status among symptomatic individuals, all patients with suspected or confirmed COVID-19 infection who underwent an obstetric inpatient evaluation or admission from March 10 through April 14, 2020, were analyzed. The study was approved by our institutional review board.

RESULTS

From April 1 through April 14, 2020, there were 213 admissions to obstetric services. Of those patients with complete blood count results, 172 (84.3%) had a WBC count differential performed. The absolute lymphocyte count ranged from 0.5 to $6.0 \times 10^3/\text{microliter}$

From the Departments of Obstetrics and Gynecology and Anesthesia, Critical Care and Pain Medicine, and the Division of Infectious Diseases, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts

This work was conducted with support from Harvard Catalyst/The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health Award UL 1TR002541) and financial contributions from Harvard University and its affiliated academic healthcare centers.

Each author has confirmed compliance with the journal's requirements for authorship.

Corresponding author: Blair J. Wylie, MD, MPH, Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02115; email: bwylie@bidmc.harvard.edu.

Financial Disclosure

Anna M. Modest disclosed receiving a grant from Charles Koch Foundation, but not for this study. Michele R. Hacker received money paid to her institution from NIEHS and the Charles Koch Foundation. She also disclosed having additional financial relationships with the Society for Family Planning, Breast Cancer Research Foundation, William F Milton Fund, and Affiliates Risk Management Services, Inc. Toni Golen received money paid to their institution from Harvard Health Publishing and money was paid to them for medical legal consulting. Scott Shainker has received funding from the Charles Koch Foundation. Rebecca Zash disclosed that money was paid to her institution from the NIH/NICHD and money was paid to her from Virology Education. Blair Wylie serves on the board of the Society for Maternal-Fetal Medicine and has received research grant funding paid to her institution from NIEHS, NIAID, and the Gates Foundation. The other authors did not report any potential conflicts of interest.

© 2020 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.

ISSN: 0029-7844/20



Table 1. Maternal Demographics and Blood Count Characteristics of Obstetric Patients With a Complete Blood Count and White Blood Cell Count Differential Performed on Admission (N=172)

Characteristic	Value
Age (y)	33.0 (30.4–36.3)
Race	
White	69 (40.1)
Black	17 (9.9)
Hispanic	17 (9.9)
Asian	20 (11.6)
Other or unknown	49 (28.5)
Insurance	
Public	10 (5.8)
Private or self-pay	161 (93.6)
Unknown	1 (0.6)
Laboratory values	
RBC count (m/microliter)	4.0 (3.7–4.2)
Hematocrit (%)	36.1 (33.7–38.4)
Hemoglobin (g/dL)	11.9 (11.0–12.7)
Platelet count ($\times 10^3$ /microliter)	211.5 (178.0–263.0)
WBC count ($\times 10^3$ /microliter)	10.8 (8.9–12.8)
Lymphocytes (%)	17.1 (13.4–23.1)
Less than 19	99 (57.6)
Absolute lymphocytes ($\times 10^3$ /microliter)	1.8 (1.3–2.3)
Less than 0.8	8 (4.7)
Less than 1.0	16 (9.3)

RBC, red blood cell; WBC, white blood cell. Data are median (interquartile range) or n (%).

(median 1.8×10^3 /microliter, interquartile range 1.3–2.3, Table 1). Nine patients had lymphopenia; six of these had suspected or known COVID-19 infection. The remaining three patients were asymptomatic and had negative COVID-19 test results. None of these patients developed symptoms during admission.

From March 10 through April 14, 2020, 37 symptomatic patients with known or suspected COVID-19 infection presented for inpatient evaluation or admission. All underwent COVID-19 testing. Of the 37 patients, one had an insufficient sample,

15 (41%) had positive test results, and 21 (57%) had negative test results. Of the 36 patients with test results, 31 had an absolute lymphocyte count performed at admission, with a COVID-19 infection prevalence of 48% (15/31). There was no difference in median absolute lymphocyte count in symptomatic patients with and without COVID-19 infection (1.1 vs 1.4×10^3 /microliter, $P=.11$). Among 15 patients with confirmed COVID-19 infection, 33% had an absolute lymphocyte count less than 0.8×10^3 /microliter, compared with 25% among the 16 patients with negative test results ($P=.70$). Of note, all three patients who required critical care for hypoxia in our cohort had an initial absolute lymphocyte count less than 0.8×10^3 /microliter. Test performance characteristics for three definitions of lymphopenia to identify COVID-19 infection are shown in Table 2. At a COVID-19 infection prevalence of 48%, the positive predictive value for each definition was less than 60%.

DISCUSSION

Lymphopenia (defined as absolute lymphocyte count less than 0.8×10^3 /microliter) was an uncommon finding among obstetric inpatients and was not a useful screening strategy for identifying asymptomatic SARS-CoV-2 infection. Moreover, absolute lymphocyte count did not meaningfully discriminate those with and without infection among patients under investigation. Lymphopenia is a common feature of many viral infections, including including infection with SARS-CoV-2, and may result from direct infection of lymphocytes or immunologically mediated cell apoptosis.¹⁰ Although lymphopenia was more common in symptomatic patients with confirmed COVID-19 infection, this was not a great marker of disease. We did observe that lymphopenia was consistently present in patients presenting with severe disease, an association that has been reported frequently in nonpregnant patients with COVID-19 infection (Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. Lymphopenia predicts disease severity of

Table 2. Test Characteristics of Primary and Alternative Definitions of Lymphopenia in Predicting Coronavirus Disease 2019 (COVID-19) Infection Among 31 Symptomatic Patients, With COVID-19 Infection Prevalence of 48%

Lymphopenia Definition	Sensitivity	Specificity	PPV	NPV
ALC ($\times 10^3$ /microliter)				
Less than 0.8	33 (12–62)	75 (48–93)	56 (21–86)	55 (32–76)
Less than 1.0	47 (21–73)	69 (41–89)	58 (28–85)	58 (34–80)
Lymphocytes less than 19%	87 (60–98)	19 (4–46)	50 (30–70)	60 (15–95)

PPV, positive predictive value; NPV, negative predictive value; ALC, absolute lymphocyte count. Data are % (95% CI).



COVID-19: a descriptive and predictive study [letter] [published erratum appears in *Signal Transduct Target Ther* 2020;5:61.]. *Signal Transduct Target Ther* 2020;5:33.¹¹⁻¹³ Our results should be interpreted in the context of our small sample size and unknown community disease prevalence but do add to the limited studies of WBC count indices in pregnancy.¹⁴⁻¹⁶

Labor units continue to care for high volumes of patients, and the care provided involves close and frequent contact with health care workers and the possibility of unanticipated emergency surgery. Universal COVID-19 testing may be necessary to identify asymptomatic infections in areas with active community transmission. The decision to implement universal testing may require knowledge of local prevalence rates given the possibility of false-positive results in the setting of low prevalence.

REFERENCES

1. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-NCoV infection from an asymptomatic contact in Germany. *N Engl J Med* 2020;382:970-1.
2. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19. *JAMA* 2020; 323:1406-7.
3. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (COVID-19). *Science* 2020;368:489-93.
4. Sutton D, Fuchs K, D'Alton M, Goffman D. Universal screening for SARS-CoV-2 in women admitted for delivery. *N Engl J Med* 2020 Apr 13 [Epub ahead of print].
5. Breslin N, Baptiste C, Miller R, Fuchs K, Goffman D, Gyamfi-Bannerman C, et al. COVID-19 in pregnancy: early lessons. *Am J Obstet Gynecol MFM* 2020 Mar 27 [Epub ahead of print].
6. Breslin N, Baptiste C, Gyamfi-Bannerman C, Miller R, Martinez R, Bernstein K, et al. Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals. *Am J Obstet Gynecol MFM* 2020 Apr 9 [Epub ahead of print].
7. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 2020;323:1061-9.
8. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020;382:1708-20.
9. Guan W, Ni Z, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020;382:1708-20.
10. Panesar NS. What caused lymphopenia in SARS and how reliable is the lymphokine status in glucocorticoid-treated patients? *Med Hypotheses* 2008;71:298-301.
11. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497-506.
12. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* 2020;8: 475-81.
13. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ* 2020;368:m1091.
14. Lurie S, Rahamim E, Piper I, Golan A, Sadan O. Total and differential leukocyte counts percentiles in normal pregnancy. *Eur J Obstet Gynecol Reprod Biol* 2008;136:16-9.
15. Tallon DF, Corcoran DJ, O'Dwyer EM, Grealley JF. Circulating lymphocyte subpopulations in pregnancy: a longitudinal study. *J Immunol* 1984;132:1784-7.
16. Lurie S, Weiner E, Golan A, Sadan O. Total and differential leukocyte count percentiles in healthy singleton term women during the first stage of labor. *Gynecol Obstet Invest* 2014;78: 251-4.

PEER REVIEW HISTORY

Received April 26, 2020. Received in revised form May 3, 2020. Accepted May 7, 2020. Peer reviews and author correspondence are available at <http://links.lww.com/AOG/B917>.

